Protecting Enamel when Saliva Runs Dry
Few pharmaceutical developments have entered public consciousness as rapidly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Semaglutide, better known in the UK by the trade names Ozempic and Wegovy, is now a familiar presence across news feeds, social media and advertising platforms. Originally developed for the treatment of type 2 diabetes, GLP-1 RAs are now widely used in the management of obesity.[i] As their use has expanded, concerns have emerged regarding gastrointestinal adverse events and associated oral symptoms, including xerostomia.[ii],[iii]
These may have important consequences for oral health and quality of life, yet remarkably the long-term dental impact of this drug class remains poorly characterised. Current evidence is largely drawn from clinical trials, case reports and anecdotal accounts, meaning the true prevalence may be underestimated. This places dentists in the unique position of being among the first to recognise early signs and offer preventive advice.
Ozempic mouth
The informal term “Ozempic mouth” describes a range of reported oral symptoms associated with GLP-1 RA treatment, including xerostomia, altered taste and halitosis.[iv] Gastrointestinal adverse effects such as reflux, eructation and vomiting may also contribute to unpleasant breath and dental erosion. A drier oral environment may disturb the oral microbiome, favouring bacteria associated with caries, halitosis and periodontal inflammation such as Porphyromonas gingivalis and Streptococcus mutans.[iv]
Mechanistic mystery
Precisely why some patients experience xerostomia during GLP-1 RA treatment is not yet understood. Proposed explanations include direct effects of GLP-1 receptor signalling within the salivary glands, although this remains hypothetical.[v] Indirect factors such as nausea, vomiting, reduced appetite and lower fluid intake may play a role.[iv] It remains unclear whether symptoms reflect a subjective sensation of oral dryness, objectively reduced salivary flow, or a combination of both.[v]
Symptoms may be underreported because patients are unaware of the possible associations or attribute oral dryness to other factors such as perimenopause, nicotine-replacement therapy or concurrent xerogenic medication.
The secret of saliva
Saliva plays a central role in maintaining oral homeostasis. It lubricates the oral tissues, supports swallowing and speech, clears food debris, buffers plaque acids and supplies minerals needed for enamel health.[vii] When salivary flow is reduced, this protective system becomes less effective, leaving the teeth more vulnerable to acid challenge.
The adverse-effect profile of GLP-1 RAs may create several overlapping risks. Reflux and vomiting expose enamel directly to gastric acid, while xerostomia reduces the buffering capacity that would ordinarily limit damage. Some patients lean towards grazing to manage nausea, and this repeated carbohydrate intake can provide cariogenic bacteria with a regular supply of fermentable substrate, increasing the frequency of plaque-acid attacks.[iv]
However, the overall effect is unlikely to be uniform. Improved glycaemic control may reduce salivary glucose and support oral immune function, while reduced food and carbohydrate intake could lower cariogenic exposure. Individual risk therefore depends on the complex balance between salivary changes, vomiting or reflux, dietary behaviour and baseline susceptibility to caries and erosion.
Beyond enamel damage, xerostomia may contribute to reduced quality of life. This can become a double-edged sword: unpleasant adverse effects may reduce patients’ motivation to continue GLP-1 RA treatment, potentially undermining improvements in obesity or type 2 diabetes management.[viii]
This may create a clinically important feedback loop. Loss of the benefits associated with improved glycaemic control and reduced dietary intake could re-expose patients to the very metabolic and behavioural factors that can increase caries risk.
Understanding and managing risk
When taking a medical history, dental professionals should ask patients using GLP-1 RAs about relevant oral and gastrointestinal symptoms, as they may not report these without prompting. Management should be guided by individual risk with closer monitoring for caries and erosive wear, particularly on the palatal surfaces of the maxillary teeth.
Preventive advice currently includes rinsing with water or sodium bicarbonate solution after vomiting and delaying brushing for 30-60 minutes to avoid abrading acid-softened enamel.[iv] Xerostomia management may include adequate hydration, xylitol-containing salivary stimulants and saliva substitutes, alongside advice to reduce excessive snacking on fermentable carbohydrates.
For patients whose natural salivary protection is reduced, the balance between demineralisation and remineralisation can shift towards mineral loss.[ix] A toothpaste capable of providing a sustained supply of mineral ions may therefore offer valuable additional support. BioMin® F contains fluorocalcium phosphosilicate, a fluoride containing bioactive glass designed to bond to the tooth surface and gradually release calcium, phosphate and fluoride ions for up to 12 hours.[x] Importantly, this release is pH-responsive: as acidity increases, the glass dissolves more rapidly, providing an increased supply of mineral ions when the tooth surface is under greater acid challenge. Calcium and phosphate are central to the natural remineralisation process, helping to rebuild lost mineral in tooth enamel. When fluoride is present alongside them, it supports the formation of fluorapatite, which is more resistant to acid attack. By combining sustained mineral availability with increased release under acidic conditions, BioMin® F provides additional mineral support where natural salivary protection may be compromised.
GLP-1 RAs may offer substantial systemic benefits in the management of obesity and type 2 diabetes, but their possible oral effects should not be overlooked. Early recognition of xerostomia and preventive care may help preserve enamel over the long term for patients. The evidence may be immature, but enamel protection should not wait for certainty.
